Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylamine SCHEMBL1685445 | 0.97 | TDP1 (0.53) | TDP1DNM1ALDH1A1MEN1KMT2A | |
| Ethylamine SCHEMBL612047 | 0.83 | TDP1 (0.61) | TDP1ALDH1A1 | |
| Butylamine SCHEMBL2810676 | 0.82 | DNM1 (0.48) | TDP1DNM1ALDH1A1MEN1KMT2A | |
| Monoethanolamine SCHEMBL28173374 | 0.79 | TSHR (0.47) | TDP1ALDH1A1TSHR | |
| SCHEMBL9585360 | 0.78 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL39184 | 0.75 | — | — | |
| SCHEMBL28982199 | 0.75 | TDP1 (0.50) | TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL3755489 | 0.75 | — | — | |
| Heptane SCHEMBL2515743 | 0.75 | TSHR (0.50) | TDP1DNM1ALDH1A1MEN1KMT2A | |
| Propylamine SCHEMBL1173466 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189718-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198736-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR1A, POLR2A, POLR2E | TDP1 53/4885DNM1 1246/4885ALDH1A1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.